Medicine and Dentistry
Graft Versus Host Reaction
67%
Hematopoietic Stem Cell Transplantation
67%
Alemtuzumab
47%
Mycosis
39%
Epstein Barr Virus
35%
Chimeric Antigen Receptor T-Cell
32%
Posttransplant Lymphoproliferative Disease
30%
Allogeneic Hematopoietic Stem Cell Transplantation
29%
Thymocyte Antibody
29%
Aplastic Anemia
27%
Acute Myeloid Leukemia
26%
Acute B-Cell Lymphoblastic Leukemia
26%
COVID-19
26%
Multiple Sclerosis
26%
Vein Occlusion
26%
Hematology
26%
Allogeneic Stem Cell Transplantation
26%
T Cell
25%
Diseases
25%
Liver Venoocclusive Disease
24%
Overall Survival
24%
Reduced Intensity Conditioning
20%
Hematologic Malignancy
17%
Chimeric Antigen Receptor T-Cell Therapy
17%
Cytokine Release Syndrome
17%
Virus Reactivation
17%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Cell Lineage
16%
Malignant Neoplasm
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
15%
Donor Lymphocyte Infusion
14%
Myelodysplastic Syndrome
14%
Antifungal Therapy
14%
Clinical Significance
14%
Antileukemic Agent
14%
Immunosuppressive Treatment
13%
Follicular Lymphoma
13%
Chronic Myelogenous Leukemia
13%
Gut
13%
Quality of Life
13%
Renal Failure
13%
Monoclonal Gammopathy of Undetermined Significance
13%
Liver Graft
13%
Pediatrics
13%
Phosphotransferase
13%
Cell Transplantation
13%
Cord Blood Stem Cell Transplantation
13%
Next Generation Sequencing
13%
Oncologist
13%
Comorbidity
13%
Immunology and Microbiology
Alemtuzumab
100%
Aplastic Anemia
83%
Graft-Versus-Host Disease
77%
Allogeneic Hematopoietic Stem Cell Transplantation
65%
Conditioning
62%
Hematopoietic Stem Cell Transplantation
61%
Overall Survival
43%
Allogeneic Stem Cell Transplantation
39%
Anti-Thymocyte Globulin
39%
T Cell
29%
Cyclophosphamide
28%
B Cell
26%
CD19
26%
Chronic Graft Versus Host Disease
21%
Lymphocyte
20%
Chimeric Antigen Receptor T-Cell Therapy
15%
Drug Megadose
15%
Cord Blood Stem Cell Transplantation
13%
Cell Lineage
13%
Cytotoxic T-Cell
13%
Tyrosine
13%
Stem Cell Transplantation
13%
Cytokine
13%
Multiple Myeloma
13%
Prevalence
13%
Chimeric Antigen Receptor T-Cell
13%
Inflammatory Bowel Disease
13%
Cell Transplantation
13%
Hematopoietic Cell
13%
Epstein Barr Virus
13%
Plerixafor
13%
Virus Reactivation
13%
Multiple Sclerosis
13%
CD3 Antigen
11%
Stem Cell
10%
CCL2
9%
Vedolizumab
9%
CXCR3
9%
Comorbidity
9%
Cytokine Release Syndrome
9%
Stem Cell Transplant
9%
CD4
8%
Hematocrit
6%
Polymerase Chain Reaction
6%
Umbilical Vein
6%
Hemoglobin
6%
Abscess
6%
Somatic Mutation
6%
Pancreatitis
6%
Allele
6%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
85%
Aplastic Anemia
66%
Graft Versus Host Reaction
37%
Overall Survival
34%
Fludarabine
27%
Cyclophosphamide
26%
Itraconazole
26%
Acute Lymphoblastic Leukemia
26%
Chimeric Antigen Receptor
26%
Thymocyte Antibody
26%
Retrospective Study
20%
Chronic Graft Versus Host Disease
18%
Janus Kinase
17%
Infection
16%
Comorbidity
16%
SARS Coronavirus
15%
Diseases
14%
Remission
14%
Cytokine Release Syndrome
13%
Myelodysplastic Syndrome
13%
Vein Thrombosis
13%
Voriconazole
13%
Acute Myeloid Leukemia
13%
Posaconazole
13%
Protein Tyrosine Kinase
13%
Myeloma
13%
Prevalence
13%
CD8 Antigen
13%
High Performance Liquid Chromatography
13%
Kidney Failure
13%
Plerixafor
13%
Hydroxyitraconazole
13%
Myeloproliferative Disorder
13%
Myelofibrosis
13%
Chronic Myeloid Leukemia
13%
Malignant Neoplasm
13%
Hematologic Malignancy
13%
Axicabtagene Ciloleucel
13%
Phosphotransferase
13%
Alpha Interferon
13%
Syndrome
13%
Chemotherapy
13%
Multiple Sclerosis
13%
T Cell Leukemia
13%
Zidovudine
13%
Vein Occlusion
13%
Epstein-Barr Virus
13%
Large Cell Lymphoma
13%
Antileukemic Agent
12%
Progression Free Survival
11%